This week's roundup of Houston innovators includes Aaron Knape of sEATz, Ivery Boston III of Houston Exponential, and Jesse Martinez of the LatinX Startup Alliance. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sportstech to startup-focused nonprofit work — recently making headlines in Houston innovation.

Aaron Knape, CEO and co-founder of sEATz

Aaron Knape joins the Houston Innovators Podcast to share how he's taking the sEATz platform into a new vertical. Photo courtesy of sEATz

Although sEATz was founded in 2018, Aaron Knape, CEO and co-founder, says it's only now that the company is really coming into its own as a startup ready to scale in a big way.

"I tell the team that we're kind of coming out of stealth mode — I know we're not in a true stealth mode, but we haven't spent a lot of money on sales and marketing," Knape says on this week's episode of the Houston Innovators Podcast. "Now it's time to start putting that emphasis on who we are, that we're here, and we're ready to take over."

Knape joins the show to discuss sEATz's expansion into health care and what's next for the growing company. Click here to read more and stream the podcast.

Ivery Boston III, director of inclusive innovation at Houston Exponential

Ivery Boston III joins HX to lead inclusive efforts. Photo via LinkedIn

Houston Exponential made a new hire to reflect on the city's diversity. Ivery Boston III is one week into his role as HX's director of inclusive innovation. He will be tasked with leading prototyping and testing new inclusive ideas and ways of operating, according to a news release from HX. He will also be responsible for creating opportunities for underrepresented founders to succeed in Houston.

Boston joins HX from Miami, where he led research, strategy, recruitment of high-growth startups, and impact reporting for the Miami Downtown Development Authority.

"I am excited to serve the Houston community as the director of inclusive innovation at Houston Exponential," says Boston in the release. "I'm a massive fan of HX's work advocating for, connecting, and raising the profile of the Houston innovation ecosystem while linking local founders to funding. It is a privilege to join this exemplary team and provide additional attention to underrepresented and under-encouraged founders within the city." Click here to read more.

Jesse Martinez, founder of the LatinX Startup Alliance

Jesse Martinez, founder of the LatinX Startup Alliance, joins InnovationMap for a Q&A on why he's relocating his nonprofit to Houston. Photo courtesy of LSA

Wheen Jesse Martinez was looking for startup support as a Latino founder, he couldn't find it. So, he took the initiative to make it himself and launched the LatinX Startup Alliance. The Houston native announced his plans to relocate his Silicon Valley nonprofit to The Ion next year.

He tells InnovationMap why he thinks Houston is the right market for LSA.

"We're on the ground floor. We're helping to build that foundation. It's not an afterthought. It's not something that now we're trying to go back and think of diversity," Martinez tells InnovationMap. "I think that's the beautiful thing about Houston and everyone that I've met is that it's been so diverse and inclusive. That spirit is already there. So, how do we just maximize that?" Click here to read the full Q&A.

Ivery Boston III joins HX to lead inclusive efforts. Photo via LinkedIn

Houston Exponential hires new exec to promote inclusive innovation

new to hou

Houston's considered one of the most diverse cities in the country, and Houston Exponential is focused on building an innovation ecosystem that's reflective of that.

The nonprofit organization announced a new hire that will lead this initiative. Ivery Boston III started this week as HX's director of inclusive innovation. He will be tasked with leading prototyping and testing new inclusive ideas and ways of operating, according to a news release from HX. He will also be responsible for creating opportunities for underrepresented founders to succeed in Houston.

"Other cities, in their dogged pursuit of being the next 'Silicon Valley,' followed the coastal playbook and weren't deliberate to support underserved entrepreneurs," says Serafina Lalany, executive director of Houston Exponential, in the release. "There is still much work to be done to address subtle and persistent forms of bias in the ways underrepresented founders access the resources, capital, and talent needed to thrive here in Houston. This move, for Houston Exponential and for the City of Houston, is part of an intentional strategy to foster a more inclusive, accessible ecosystem."

Boston joins HX from Miami, where he led research, strategy, recruitment of high-growth startups, and impact reporting for the Miami Downtown Development Authority.

"I am excited to serve the Houston community as the director of inclusive innovation at Houston Exponential," says Boston in the release. "I'm a massive fan of HX's work advocating for, connecting, and raising the profile of the Houston innovation ecosystem while linking local founders to funding. It is a privilege to join this exemplary team and provide additional attention to underrepresented and under-encouraged founders within the city."

Boston has also worked with Indeed.com, Zipcar, Sodexo, and other companies within market reporting. He attended Temple University.

"I look forward to rolling up my sleeves and ensuring that all Houstonians can see a viable path to entrepreneurship," he continues. "It's time to leverage Houston's diversity to bring in additional funding sources, create jobs, and use the profound local awareness of the world to launch businesses, services, and products that serve the global market."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.